For the year ending 2025-12-31, PTCT made $1,730,655K in revenue. $682,644K in net income. Net profit margin of 39.44%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Total revenues | 1,730,655 | 805,119 | ||
| Intangible asset impairment | - | 159,548 | ||
| Cost of product, collaboration and license sales, excluding amortization of acquired intangible assets | 47,013 | 57,398 | ||
| Amortization of acquired intangible assets | 24,742 | 60,738 | ||
| Research and development | 455,249 | 534,480 | ||
| Selling, general and administrative | 347,143 | 300,911 | ||
| Change in the fair value of contingent consideration | 800 | 4,475 | ||
| Tangible asset impairment and (gains) losses on transactions, net | 9,627 | -750 | ||
| Total operating expenses | 863,720 | 1,109,350 | ||
| Income (loss) from operations | 866,935 | -302,570 | ||
| Gain on sale of priority review voucher | - | 99,900 | ||
| Interest expense, net | -152,230 | -166,993 | ||
| Other (expense) income, net | -18,086 | 6,544 | ||
| Income (loss) before income tax (expense) benefit | 696,619 | -363,119 | ||
| Income tax (expense) benefit | 13,975 | 176 | ||
| Net income (loss) attributable to common stockholders | 682,644 | -363,295 | ||
| Basic EPS | 8.58 | -4.73 | ||
| Diluted EPS | 7.78 | -4.73 | ||
| Basic Average Shares | 79,534,290 | 76,845,055 | ||
| Diluted Average Shares | 88,311,494 | 76,845,055 | ||
PTC THERAPEUTICS, INC. (PTCT)
PTC THERAPEUTICS, INC. (PTCT)